GenDx Obtains World Wide Distribution Rights of QIAGEN® LongRange PCR Kit
News May 16, 2012
On April 26th, QIAGEN has granted GenDx the non-exclusive rights to distribute world-wide, both direct and via third parties, the QIAGEN LongRange PCR kit in combination with the SBTexcellerator® reagents for high resolution HLA typing.
This elevates the cooperation between QIAGEN and GenDx and shows the commitment of both companies to facilitate the tissue typing community world wide with the highest quality products.
The QIAGEN LongRange PCR kit in combination with the GenDx SBTexcellerator® reagents enables amplification of the HLA genes beyond the classic exon 2, 3 and 4 regions.
Thereby, other important regions of the HLA genes can also be identified by sequencing. This provides tissue typers the ultimate tools to achieve the highest resolution of HLA typing and minimize the number of ambiguities.
Wietse Mulder, Managing Director of GenDx commented: “This distribution agreement enables GenDx and her partners to even better fulfil the requirements of our customers worldwide to efficiently obtain reliable HLA-typing results.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.